Short Interest in Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Grows By 90.3%

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) was the recipient of a large growth in short interest during the month of August. As of August 31st, there was short interest totaling 27,111 shares, a growth of 90.3% from the August 15th total of 14,245 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average trading volume of 331,733 shares, the days-to-cover ratio is presently 0.1 days.

Chugai Pharmaceutical Trading Up 0.1%

Shares of OTCMKTS CHGCY opened at $20.78 on Wednesday. The firm has a fifty day simple moving average of $21.78 and a two-hundred day simple moving average of $24.58. The firm has a market capitalization of $68.40 billion, a PE ratio of 22.59 and a beta of 0.59. Chugai Pharmaceutical has a 12 month low of $20.00 and a 12 month high of $34.84.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its earnings results on Friday, July 24th. The company reported $0.22 earnings per share for the quarter. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.76%. The firm had revenue of $2.14 billion for the quarter, compared to the consensus estimate of $2.38 billion. On average, sell-side analysts predict that Chugai Pharmaceutical will post 0.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on CHGCY. The Goldman Sachs Group raised shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Monday, June 15th. Nomura upgraded Chugai Pharmaceutical to a “hold” rating in a research report on Tuesday, September 1st. Zacks Research upgraded Chugai Pharmaceutical to a “hold” rating in a research report on Friday, May 29th. Finally, UBS Group downgraded shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy”.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Tokyo. Founded in 1925, the company focuses on discovering, developing, manufacturing and commercializing prescription medicines, with an emphasis on biotechnology and innovative therapies for serious and unmet medical needs.

Chugai’s principal therapeutic areas include oncology, hematology, immunology, neuroscience and renal diseases. Its products include Actemra (known as RoActemra in some markets) for inflammatory and immune-related conditions, Hemlibra for hemophilia A, and Alecensa for certain forms of lung cancer.